🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer

Recruitingn/aAges 18 Years - anyAllEDUARDO ALBENIZ
NCT05551416 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric neoplasias (EGC) treated by endoscopy resection; and no less than 600 healthy normal cohort participants, for more than 18 months in the Spanish population. All participants who enrolled in this registry will be questioned by the life habits survey; and clinical data and biological samples of these participants were analyzed in order to look for new diagnostic tools. The aim of this study is to evaluate clinical, endoscopic and molecular approaches to identify individuals with high-risk of GC. Thus, it would be allow the adoption of preventive measures to reduce mortality through early detection and/or the reduction of its incidence.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults over 18 years-old. * EDGAR 1 cohort: symptomatic patients undergoing a diagnostic gastroscopy for a prevalence study of PGLs. * EDGAR 2 cohort: PGLs and early GC with indication for endoscopic resection. * EPIGASTRIC cohort: patients diagnosed with GC. * CONTROL cohort: patients without gastric pathology or a familial history of GC, obtained from the EDGAR 1. Exclusion Criteria: * Refusal of the patient to participate in the study. * Medical, psychological or legal inability of the patient to enter the study. * EDGAR1: Previous diagnosis of PGLs, previous gastric surgery, contraindication for gastroscopy or taking biopsies. * EDGAR 2: Contraindication for resection/biopsy. * EPIGASTRIC: gastric neoplasm other than adenocarcinoma.
💊

What it tests

  • Identification of risk factors
  • Characterization of premalignant gastric lesions
  • Identification of biomarkers
  • Identification of gastric cancer hereditary predisposition
📍

Where

15 sites
Hospital Comarcal de Inca
Palma de Mallorca, Spain
Hospital de Llevant
Porto Cristo, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital General de Granollers
Granollers, Spain
Consorci Sanitari de Terrassa
Terrassa, Spain
Hospital Santos Reyes
Aranda de Duero, Spain
Hospital Universitario de Burgos
Burgos, Spain
Hospital de Mérida
Mérida, Spain

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy